Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial

Abstract Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a challenging side effect, significantly impacting patients' quality of life [1–3]. Knowledge of eating behaviour’s influence on CINV is still limited. This study improves the understanding of CINV by investigating the impact of pre-chemotherapy food intake within the randomized Phase III SUCCESS C trial. Methods The SUCCESS C trial (NCT00847444), enrolled ,463 women with early-stage, HER2-negative breast cancer, receiving either three cycles of 5-fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ) followed by three cycles of docetaxel (100 mg/m 2 ) every 3 weeks (FEC), or six cycles of docetaxel (75 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) (TC). The present analysis included patients with completed CINV diary with hourly documentation over 5 days post-chemotherapy. Results CINV diary data during chemotherapy cycles 1–3 were available for 1582 patients, of whom 814 received FEC and 768 TC. Patient characteristics between chemotherapy arms were comparable. For FEC, pre-chemotherapy eating behaviour had a significant impact on nausea-free survival (NFS) in cycle 1 ( p = 0.04) and on emesis-free survival (EFS) in cycle 2 ( p = 0.02). For TC, no effect on NFS, but a significant effect on EFS ( p = 0.04 in cycle 1; p < 0.01 in cycle 2), was observed. Median EFS was approximately 120 h for all cycles and treatments. Conclusion This analysis demonstrates in both regimens less emesis, and for FEC less nausea, of patients with pre-chemotherapy food intake. The effect was most pronounced during the first 24 h after chemotherapy administration. Thus, eating behaviour influences CINV outcomes and warrants further evaluation.

Authors

Institutions

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-13
DOI
https://doi.org/10.1007/s00520-026-11437-9
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial

Brigitte Kathrin Rack, Elena Leinert, Uwe Köhler, Sabine Heublein et al.
2 links
Supportive Care in Cancer
Nausea and vomiting management
article

Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial

Brigitte Kathrin Rack, Elena Leinert, Uwe Köhler, Sabine Heublein, Lothar Häberle, Wolfgang Janni, Sara Yvonne Brucker, Chloë Goossens, Henning Schäffler, Kristina Veselinovic, Andreas Schneeweiß, Manuel Hörner, Kerstin Pfister, Peter A. Fasching, Matthias W. Beckmann, Georg Heinrich, Philipp Ziegler
article en

Abstract

Abstract Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a challenging side effect, significantly impacting patients' quality of life [1–3]. Knowledge of eating behaviour’s influence on CINV is still limited. This study improves the understanding of CINV by investigating the impact of pre-chemotherapy food intake within the randomized Phase III SUCCESS C trial. Methods The SUCCESS C trial (NCT00847444), enrolled ,463 women with early-stage, HER2-negative breast cancer, receiving either three cycles of 5-fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ) followed by three cycles of docetaxel (100 mg/m 2 ) every 3 weeks (FEC), or six cycles of docetaxel (75 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) (TC). The present analysis included patients with completed CINV diary with hourly documentation over 5 days post-chemotherapy. Results CINV diary data during chemotherapy cycles 1–3 were available for 1582 patients, of whom 814 received FEC and 768 TC. Patient characteristics between chemotherapy arms were comparable. For FEC, pre-chemotherapy eating behaviour had a significant impact on nausea-free survival (NFS) in cycle 1 ( p = 0.04) and on emesis-free survival (EFS) in cycle 2 ( p = 0.02). For TC, no effect on NFS, but a significant effect on EFS ( p = 0.04 in cycle 1; p < 0.01 in cycle 2), was observed. Median EFS was approximately 120 h for all cycles and treatments. Conclusion This analysis demonstrates in both regimens less emesis, and for FEC less nausea, of patients with pre-chemotherapy food intake. The effect was most pronounced during the first 24 h after chemotherapy administration. Thus, eating behaviour influences CINV outcomes and warrants further evaluation.

Supportive Care in CancerVol. 34(12)
German Cancer Research Center (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Heidelberg University (DE), Klinikum St. Georg (DE), Universitätsklinikum Erlangen (DE), National Center for Tumor Diseases (DE), Sana Klinikum Offenbach (DE), Comprehensive Cancer Center Erlangen (DE), University Hospital Ulm (DE), University of Tübingen (DE)
Pfizer, GlaxoSmithKline, Sanofi, Universitätsklinikum Erlangen, Chugai Pharmaceutical
Good health and well-being
Nausea and vomiting management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon